<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445951</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-171</org_study_id>
    <nct_id>NCT01445951</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With a Basal Insulin Versus Insulin Aspart in Combination With a Basal Insulin in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of
      TI Inhalation Power in combination with a basal insulin versus insulin aspart in combination
      with a basal insulin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3 clinical trial designed to examine the efficacy and safety of inhaled prandial TI
      Inhalation Power in combination with basal insulin versus insulin aspart in combination with
      basal insulin in subjects with type 1 diabetes who are suboptimally controlled with their
      current insulin regimens. This trial will employ a variety of methods to intensively manage
      these subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in HbA1c</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Effect of treatment as measured by change from baseline in glycated hemoglobin (HbA1c). Primary treatment difference is TI-Gen2 vs. Insulin Aspart at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 Change From Baseline to Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Forced Expiratory Volume in 1 second - change from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline to Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Comparison of mean change from Baseline to Week 24 visit in fasting plasma glucose (FPG) levels (central laboratory results)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 7-point Glucose Baseline Values</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean 7-point glucose at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 7-point Glucose Week 24 Values</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight From Baseline to Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change in body weight from Baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Responders Achieving HbA1c &lt;= 7.0%</measure>
    <time_frame>Week 24</time_frame>
    <description>Efficacy as measured in proportion of subjects achieving HbA1c &lt; or = to 7.0%</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Total Hypoglycemia</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Hypoglycemia, defined as blood glucose &lt;= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Severe Hypoglycemia</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Severe Hypoglycemia defined as: Requiring 3rd party assistance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Hypoglycemia Event Rate</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Number of Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe Hypoglycemia Event Rate</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">518</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Technosphere® Insulin with MedTone C Inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspart Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Technosphere ® Insulin-Gen2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere® Insulin with MedTone C Inhaler</intervention_name>
    <description>Inhalation Powder and injectable insulin</description>
    <arm_group_label>Technosphere® Insulin with MedTone C Inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere ®Insulin with Gen2 Inhaler</intervention_name>
    <description>Inhalation Powder and injectable insulin</description>
    <arm_group_label>Technosphere ® Insulin-Gen2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart in combination with a basal insulin</intervention_name>
    <description>Injectable insulin</description>
    <arm_group_label>Aspart Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women = 18 years of age

          -  Clinical diagnosis of type 1 diabetes mellitus for at least 12 months

          -  Body mass index (BMI) = 38 kg/m2

          -  Stable dose of basal/bolus insulin therapy for at least 3 months with an FPG
             consistently &lt; 220 mg/dL:

          -  HbA1c = 7.5% and = 10.0%

          -  Fasting C-peptide = 0.30 pmol/mL

          -  Subject willingness to not use CGM during the entire course of the trial

          -  Nonsmoking (includes cigarettes, cigars, pipes, and chewing tobacco) for the preceding
             6 months

          -  Negative urine cotinine test, defined as = 100 ng/mL

          -  Lung function tests: • Forced expiratory volume in 1 second (FEV1) = 70% Third
             National Health and Nutrition Examination Survey (NHANES III) predicted

          -  Written informed consent

        Exclusion Criteria:

          -  Total daily insulin dose = 2 IU/kg/day. History of insulin pump use within 3 months of
             Screening or use of continuous glucose monitoring within 6 weeks of Screening

          -  History of inhaled insulin use in the previous 6 months

          -  Two or more unexplained severe hypoglycemic episodes within 3 months of Screening or
             an episode of severe hypoglycemia between Visit 1 and Visit 2. Unexplained refers to
             episodes of severe hypoglycemia that are not related to a dosing error, lack of or a
             change in meal size, or related to additional/unanticipated exercise

          -  Any hospitalization or emergency room visit due to poor diabetic control within 6
             months of Screening, or hospitalization or emergency room visit due to poor diabetic
             control between Visit 1 and Visit 2

          -  Allergy or known hypersensitivity to insulin or to any of the drugs to be used in the
             study, or a history of hypersensitivity to TI Inhalation Powder or to drugs with a
             similar chemical structure

          -  History of recent blood transfusions (within previous 3 months), hemoglobinopathies,
             or any other conditions that affect HbA1c measurements.

          -  History of COPD, asthma, or any other clinically important pulmonary disease (eg,
             pulmonary fibrosis), or use of any medications for these conditions

          -  Any clinically significant radiological findings on screening chest x-ray

          -  Active respiratory infection within 30 days before Screening (subject may return after
             30 days from resolution for rescreening)

          -  Major organ system diseases, including: ? Seizure disorder; systemic autoimmune or
             collagen vascular disease requiring previous or current treatment with systemic
             corticosteroids, cytotoxic drugs, or penicillamine; cancer (other than excised
             cutaneous basal cell carcinoma) or any history of lung neoplasms

          -  Current or previous chemotherapy or radiation therapy that may result in pulmonary
             toxicity; use of medications for weight loss (eg, sibutramine, orlistat) within 12
             weeks of Screening; treatment with amiodarone within 12 weeks of Screening

          -  Clinically significant abnormalities on screening laboratory evaluation or chest x-ray

          -  Severe complications of diabetes, in the opinion of the PI, including symptomatic
             autonomic neuropathy; disabling peripheral neuropathy; active proliferative
             retinopathy; nephropathy with renal failure, renal transplant, or dialysis;
             nontraumatic amputations due to gangrene; or vascular claudication

          -  Women who are pregnant, lactating, or planning to become pregnant during the clinical
             study period; women of childbearing potential (defined as premenopausal and not
             surgically sterilized or postmenopausal for fewer than 2 years) not practicing
             adequate birth control. Adequate birth control is defined as using oral, percutaneous,
             or transdermal contraceptives; condoms and diaphragms (double barrier) with a
             spermicide; or intrauterine devices. Postmenopausal for this study includes amenorrhea
             f

          -  Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the
             opinion of the PI, would make the subject an unsuitable candidate for participation in
             the study

          -  Exposure to any investigational medications or devices within the previous 30 days
             before study entry

          -  Unable to read or write, or unlikely to comprehend and follow the study protocol
             procedures; lack of compliance with medication or procedures that, in the PI's
             opinion, may affect the study data or subject safety and that precludes the subject
             from participation in the study; or any other concurrent medical or major psychiatric
             condition that, in the opinion of the PI, makes the subject unsuitable for the
             clinical study or could limit the validity of the informed consent or impair the
             subject'
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vincennes</city>
        <state>Indiana</state>
        <zip>47591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11365</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>Russia</state>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>Russia</state>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <state>RUS</state>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>105120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>119048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>125299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <state>RUS</state>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petrozavodsk</city>
        <state>RUS</state>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <state>RUS</state>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>RUS</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>RUS</state>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>RUS</state>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>RUS</state>
        <zip>192148</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>RUS</state>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>RUS</state>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <state>RUS</state>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <state>RUS</state>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <state>UKR</state>
        <zip>49023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <state>UKR</state>
        <zip>83114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <state>UKR</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <state>UKR</state>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <state>UKR</state>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <state>UKR</state>
        <zip>02175</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odesa</city>
        <state>UKR</state>
        <zip>65039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odesa</city>
        <state>UKR</state>
        <zip>65114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsya</city>
        <state>UKR</state>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>October 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2014</results_first_posted>
  <disposition_first_submitted>August 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 27, 2013</disposition_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient enrolled Sept 2011. Multi-national trial conducted in US, Russia, Ukraine and Brazil.</recruitment_details>
      <pre_assignment_details>3 week Screening Period prior to run-in (basal insulin optimization period). 1401 Screened / 621 Eligible of which 614 entered the run-in period. 538 met randomization criteria at end of run-in of which 518 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
          <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
        </group>
        <group group_id="P2">
          <title>Technosphere Insulin-MedTone + Basal Insulin</title>
          <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
        </group>
        <group group_id="P3">
          <title>Insulin Aspart + Basal Insulin</title>
          <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision - subject travel</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cough</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
          <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
        </group>
        <group group_id="B2">
          <title>Technosphere Insulin-MedTone + Basal Insulin</title>
          <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
        </group>
        <group group_id="B3">
          <title>Insulin Aspart + Basal Insulin</title>
          <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="174"/>
            <count group_id="B2" value="174"/>
            <count group_id="B3" value="170"/>
            <count group_id="B4" value="518"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="166"/>
                    <measurement group_id="B4" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" lower_limit="1.1" upper_limit="57.3"/>
                    <measurement group_id="B2" value="17.7" lower_limit="1.1" upper_limit="49.5"/>
                    <measurement group_id="B3" value="16.7" lower_limit="1.0" upper_limit="42.2"/>
                    <measurement group_id="B4" value="16.8" lower_limit="1.0" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.7" lower_limit="41.7" upper_limit="129.4"/>
                    <measurement group_id="B2" value="76.8" lower_limit="47.6" upper_limit="124.0"/>
                    <measurement group_id="B3" value="72.6" lower_limit="46.6" upper_limit="120.2"/>
                    <measurement group_id="B4" value="75.1" lower_limit="41.7" upper_limit="129.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" lower_limit="16.6" upper_limit="38.6"/>
                    <measurement group_id="B2" value="26.2" lower_limit="18.1" upper_limit="36.4"/>
                    <measurement group_id="B3" value="25.4" lower_limit="17.4" upper_limit="37.2"/>
                    <measurement group_id="B4" value="25.9" lower_limit="16.6" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155.0" lower_limit="21.0" upper_limit="403.0"/>
                    <measurement group_id="B2" value="144.3" lower_limit="43.0" upper_limit="358.0"/>
                    <measurement group_id="B3" value="151.2" lower_limit="23.0" upper_limit="375.0"/>
                    <measurement group_id="B4" value="150.2" lower_limit="21.0" upper_limit="403.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>Percent of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.98" lower_limit="6.20" upper_limit="10.60"/>
                    <measurement group_id="B2" value="8.00" lower_limit="6.10" upper_limit="10.20"/>
                    <measurement group_id="B3" value="7.88" lower_limit="5.80" upper_limit="10.10"/>
                    <measurement group_id="B4" value="7.95" lower_limit="5.80" upper_limit="10.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in HbA1c</title>
        <description>Effect of treatment as measured by change from baseline in glycated hemoglobin (HbA1c). Primary treatment difference is TI-Gen2 vs. Insulin Aspart at Week 24</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in HbA1c</title>
          <description>Effect of treatment as measured by change from baseline in glycated hemoglobin (HbA1c). Primary treatment difference is TI-Gen2 vs. Insulin Aspart at Week 24</description>
          <population>Full analysis set</population>
          <units>Percent of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.062"/>
                    <measurement group_id="O2" value="-0.29" spread="0.061"/>
                    <measurement group_id="O3" value="-0.40" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM (mixed model repeated measures) model with auto-regression (1): HbA1c = Baseline HbA1c + region + basal insulin stratum + visit + treatment + (visit*treatment)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority with 0.4 margin</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.086</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Change From Baseline to Week 24</title>
        <description>Forced Expiratory Volume in 1 second - change from baseline to week 24</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Change From Baseline to Week 24</title>
          <description>Forced Expiratory Volume in 1 second - change from baseline to week 24</description>
          <population>Safety population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.012"/>
                    <measurement group_id="O2" value="-0.08" spread="0.012"/>
                    <measurement group_id="O3" value="-0.04" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>Mixed Model Repeated Measure (MMRM): FEV1 = Baseline FEV1 + Age + Gender + Race + Baseline Height + Visit + Treatment + (Visit*Treatment)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline to Week 24</title>
        <description>Comparison of mean change from Baseline to Week 24 visit in fasting plasma glucose (FPG) levels (central laboratory results)</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline to Week 24</title>
          <description>Comparison of mean change from Baseline to Week 24 visit in fasting plasma glucose (FPG) levels (central laboratory results)</description>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.27" spread="7.62"/>
                    <measurement group_id="O2" value="7.15" spread="7.53"/>
                    <measurement group_id="O3" value="10.15" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-35.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.622</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.25</ci_lower_limit>
            <ci_upper_limit>-14.59</ci_upper_limit>
            <estimate_desc>MMRM: FPG = Baseline FPG + Region + Basal insulin stratum + Visit + Treatment + (Visit*Treatment)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean 7-point Glucose Baseline Values</title>
        <description>Mean 7-point glucose at baseline</description>
        <time_frame>Baseline</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Mean 7-point Glucose Baseline Values</title>
          <description>Mean 7-point glucose at baseline</description>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.1" spread="38.85"/>
                    <measurement group_id="O2" value="151.8" spread="40.32"/>
                    <measurement group_id="O3" value="147.0" spread="39.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.3" spread="48.77"/>
                    <measurement group_id="O2" value="173.5" spread="48.36"/>
                    <measurement group_id="O3" value="162.6" spread="49.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.0" spread="47.39"/>
                    <measurement group_id="O2" value="156.6" spread="42.91"/>
                    <measurement group_id="O3" value="142.3" spread="37.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.5" spread="52.25"/>
                    <measurement group_id="O2" value="169.7" spread="49.23"/>
                    <measurement group_id="O3" value="157.6" spread="48.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.9" spread="47.12"/>
                    <measurement group_id="O2" value="168.1" spread="45.24"/>
                    <measurement group_id="O3" value="154.0" spread="46.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.2" spread="51.55"/>
                    <measurement group_id="O2" value="177.0" spread="53.17"/>
                    <measurement group_id="O3" value="158.5" spread="47.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.3" spread="51.38"/>
                    <measurement group_id="O2" value="175.1" spread="43.99"/>
                    <measurement group_id="O3" value="164.4" spread="49.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean 7-point Glucose Week 24 Values</title>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Mean 7-point Glucose Week 24 Values</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.2" spread="40.64"/>
                    <measurement group_id="O2" value="147.9" spread="43.17"/>
                    <measurement group_id="O3" value="155.3" spread="48.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.7" spread="67.53"/>
                    <measurement group_id="O2" value="164.1" spread="60.97"/>
                    <measurement group_id="O3" value="163.0" spread="58.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.2" spread="56.93"/>
                    <measurement group_id="O2" value="165.9" spread="59.95"/>
                    <measurement group_id="O3" value="149.1" spread="50.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.7" spread="57.09"/>
                    <measurement group_id="O2" value="163.1" spread="50.92"/>
                    <measurement group_id="O3" value="158.2" spread="50.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.8" spread="59.96"/>
                    <measurement group_id="O2" value="177.3" spread="56.71"/>
                    <measurement group_id="O3" value="156.8" spread="48.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.8" spread="63.50"/>
                    <measurement group_id="O2" value="168.2" spread="60.77"/>
                    <measurement group_id="O3" value="157.8" spread="52.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.2" spread="62.36"/>
                    <measurement group_id="O2" value="185.6" spread="54.96"/>
                    <measurement group_id="O3" value="175.4" spread="57.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight From Baseline to Week 24</title>
        <description>Change in body weight from Baseline to Week 24</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set (subjects with data available at Baseline and at Week 24)</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline to Week 24</title>
          <description>Change in body weight from Baseline to Week 24</description>
          <population>Full analysis set (subjects with data available at Baseline and at Week 24)</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.438"/>
                    <measurement group_id="O2" value="-0.19" spread="0.428"/>
                    <measurement group_id="O3" value="0.93" spread="0.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0102</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA: Weight change from baseline = Baseline weight + Change from baseline in HbA1c + Region + Basal insulin stratum + Treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.512</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
            <estimate_desc>ANCOVA: Weight change from baseline = Baseline weight + Change from baseline in HbA1c + Region + Basal insulin stratum + Treatment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within treatment analysis of change from Baseline comparing if change was different from zero</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4955</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within treatment analysis of change from Baseline comparing if change was different from zero</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6807</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Within treatment analysis of change from Baseline comparing if change was different from zero</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Total Hypoglycemia</title>
        <description>Hypoglycemia, defined as blood glucose &lt;= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Total Hypoglycemia</title>
          <description>Hypoglycemia, defined as blood glucose &lt;= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="96.0"/>
                    <measurement group_id="O3" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Severe Hypoglycemia</title>
        <description>Severe Hypoglycemia defined as: Requiring 3rd party assistance.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Severe Hypoglycemia</title>
          <description>Severe Hypoglycemia defined as: Requiring 3rd party assistance.</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0156</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic model with affects for Region, Basal insulin stratum, and Treatment</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5328</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3198</ci_lower_limit>
            <ci_upper_limit>0.8877</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Hypoglycemia Event Rate</title>
        <description>Number of Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hypoglycemia Event Rate</title>
          <description>Number of Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
          <population>Safety population</population>
          <units>Events/Subject-Month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.80"/>
                    <measurement group_id="O2" value="10.30"/>
                    <measurement group_id="O3" value="13.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Negative Binomial Regression</method>
            <method_desc>Model: Region + Basal Insulin Stratum + Treatment + Exposure Time</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Severe Hypoglycemia Event Rate</title>
        <description>Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Hypoglycemia Event Rate</title>
          <description>Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)</description>
          <population>Safety population</population>
          <units>Events/Subject-Month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05"/>
                    <measurement group_id="O2" value="9.99"/>
                    <measurement group_id="O3" value="14.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1022</p_value>
            <method>Negative Binomial Regression</method>
            <method_desc>Model: Region + Basal Insulin Stratum + Treatment + Exposure Time</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Responders Achieving HbA1c &lt;= 7.0%</title>
        <description>Efficacy as measured in proportion of subjects achieving HbA1c &lt; or = to 7.0%</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin-Gen2 + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the Gen2 Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Technosphere Insulin-MedTone + Basal Insulin</title>
            <description>Technosphere Insulin delivered via the MedTone C Inhaler plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart + Basal Insulin</title>
            <description>Subcutaneous insulin aspart plus subcutaneous basal insulin, doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Responders Achieving HbA1c &lt;= 7.0%</title>
          <description>Efficacy as measured in proportion of subjects achieving HbA1c &lt; or = to 7.0%</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0158</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model: Treatment + Basal insulin stratum + Region + Baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.449</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>Gen2 in the numerator, Aspart in the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 24</time_frame>
      <desc>Adverse Events (AE) are summarized according to how subjects were treated, not randomized. One subject that was randomized to the Technosphere Insulin-MedTone + Basal Insulin arm was treated with Insulin aspart + Basal Insulin throughout the trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>Technosphere ® Insulin-Gen2 Group</title>
          <description>Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry
Technosphere ®Insulin with Gen2 Inhaler: Inhalation Powder and injectable insulin</description>
        </group>
        <group group_id="E2">
          <title>Technosphere® Insulin With MedTone C Inhaler</title>
          <description>Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry
Technosphere® Insulin with MedTone C Inhaler: Inhalation Powder and injectable insulin</description>
        </group>
        <group group_id="E3">
          <title>Aspart Group</title>
          <description>Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry
Insulin Aspart in combination with a basal insulin: Injectable insulin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemic Unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>MannKind Corporation</organization>
      <phone>201-983-5000</phone>
      <email>aboss@mannkindcorp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

